Losartan prevents the elevation of blood pressure in adipose-PRR deficient female mice while elevated circulating sPRR activates the renin-angiotensin system.
Adipose Tissue
/ drug effects
Angiotensin II
/ blood
Angiotensin II Type 1 Receptor Blockers
/ pharmacology
Angiotensinogen
/ genetics
Animals
Antihypertensive Agents
/ pharmacology
Blood Pressure
Female
Kidney
/ drug effects
Liver
/ drug effects
Losartan
/ pharmacology
Mice
Mice, Inbred C57BL
Receptors, Cell Surface
/ blood
Renin-Angiotensin System
Vasopressins
/ pharmacology
Prorenin Receptor
adipose tissue
hypertension
prorenin receptor
soluble prorenin receptor
vasopressin
Journal
American journal of physiology. Heart and circulatory physiology
ISSN: 1522-1539
Titre abrégé: Am J Physiol Heart Circ Physiol
Pays: United States
ID NLM: 100901228
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
pubmed:
15
12
2018
medline:
15
2
2020
entrez:
15
12
2018
Statut:
ppublish
Résumé
Deletion of the prorenin receptor (PRR) in adipose tissue elevates systolic blood pressure (SBP) and the circulating soluble form of PRR (sPRR) in male mice fed a high-fat (HF) diet. However, sex differences in the contribution of adipose-PRR and sPRR to the regulation of the renin-angiotensin system (RAS) in key organs for blood pressure control are undefined. Therefore, we assessed blood pressure and the systemic and intrarenal RAS status in adipose-PRR knockout (KO) female mice. Blockade of RAS with losartan blunted SBP elevation in HF diet-fed adipose-PRR KO mice. ANG II levels were significantly increased in the renal cortex of HF diet-fed adipose-PRR KO female mice, but not systemically. HF diet-fed adipose-PRR KO mice exhibited higher vasopressin levels, water retention, and lower urine output than wild-type (WT) mice. The results also showed that deletion of adipose-PRR increased circulating sPRR and total hepatic sPRR contents, suggesting the liver as a major source of elevated plasma sPRR in adipose-PRR KO mice. To mimic the elevation of circulating sPRR and define the direct contribution of systemic sPRR to the regulation of the RAS and vasopressin, C57BL/6 female mice fed a standard diet were infused with recombinant sPRR. sPRR infusion increased plasma renin levels, renal and hepatic angiotensinogen expression, and vasopressin. Together, these results demonstrate that the deletion of adipose-PRR induced an elevation of SBP likely mediated by an intrarenal ANG II-dependent mechanism and that sPRR participates in RAS regulation and body fluid homeostasis via its capacity to activate the RAS and increase vasopressin levels. NEW & NOTEWORTHY The elevation of systolic blood pressure appears to be primarily mediated by cortical ANG II in high-fat diet-fed adipose-prorenin receptor knockout female mice. In addition, our data support a role for soluble prorenin receptor in renin-angiotensin system activation and vasopressin regulation.
Identifiants
pubmed: 30550352
doi: 10.1152/ajpheart.00473.2018
pmc: PMC6734055
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Antihypertensive Agents
0
Receptors, Cell Surface
0
Vasopressins
11000-17-2
Angiotensinogen
11002-13-4
Angiotensin II
11128-99-7
Losartan
JMS50MPO89
Prorenin Receptor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
H506-H515Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103527
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM127211
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142969
Pays : United States
Références
J Renin Angiotensin Aldosterone Syst. 2006 Jun;7(2):74-86
pubmed: 17083061
Hypertension. 2001 May;37(5):1199-208
pubmed: 11358929
Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F521-F534
pubmed: 29667908
Hypertension. 2015 Oct;66(4):836-42
pubmed: 26303292
Int J Mol Med. 2006 Sep;18(3):483-8
pubmed: 16865234
J Hypertens. 2008 Jul;26(7):1379-89
pubmed: 18551014
J Epithel Biol Pharmacol. 2009 Jan 1;2(7):23
pubmed: 20151042
Trends Endocrinol Metab. 2014 Jun;25(6):293-302
pubmed: 24793638
Kidney Int. 2010 Nov;78(9):849-56
pubmed: 20736986
Hypertension. 2000 Mar;35(3):740-5
pubmed: 10720588
Hypertension. 2016 Jul;68(1):213-9
pubmed: 27185751
J Clin Invest. 2002 Jun;109(11):1417-27
pubmed: 12045255
Am J Physiol. 1987 Mar;252(3 Pt 2):H628-37
pubmed: 3826404
Am J Physiol Regul Integr Comp Physiol. 2011 Oct;301(4):R1067-77
pubmed: 21753145
Hypertension. 2015 Feb;65(2):352-61
pubmed: 25421983
Europace. 2009 Jun;11(6):763-9
pubmed: 19376819
Mol Cell Biol. 2012 Mar;32(6):1099-111
pubmed: 22269949
Blood Press. 1994 Jul;3(4):260-4
pubmed: 7994452
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1898-906
pubmed: 26984496
PLoS One. 2017 Dec 14;12(12):e0189696
pubmed: 29240802
Dis Model Mech. 2009 Nov-Dec;2(11-12):554-62
pubmed: 19892886
J Neuroendocrinol. 2010 May;22(5):453-9
pubmed: 20163518
J Clin Hypertens (Greenwich). 2013 Jan;15(1):14-33
pubmed: 23282121
Curr Opin Nephrol Hypertens. 2018 Mar;27(2):77-82
pubmed: 29346132
J Biol Chem. 2012 Jan 2;287(1):660-71
pubmed: 22086923
FASEB J. 2014 Oct;28(10):4408-19
pubmed: 25005176
Am J Physiol Renal Physiol. 2017 Dec 1;313(6):F1243-F1253
pubmed: 28814438
Curr Hypertens Rep. 2016 Apr;18(4):29
pubmed: 26951246
Clin Exp Nephrol. 2013 Dec;17(6):848-56
pubmed: 23564382
Gend Med. 2012 Aug;9(4):287-91
pubmed: 22795464
Methods Mol Biol. 2013;1065:129-39
pubmed: 23996361
Am J Physiol Regul Integr Comp Physiol. 2013 May 15;304(10):R818-28
pubmed: 23535460
Pflugers Arch. 2017 Oct;469(10):1245-1256
pubmed: 28620832
J Am Soc Nephrol. 2002 May;13(5):1131-5
pubmed: 11960999
Hypertension. 2015 Jul;66(1):68-74
pubmed: 25941340
J Endocrinol Invest. 2011 Dec;34(11):840-6
pubmed: 21483231
Hypertension. 2012 Jun;59(6):1188-94
pubmed: 22526255
Mol Cell Endocrinol. 2015 Feb 15;402:113-9
pubmed: 25578600
Am J Physiol. 1991 Nov;261(5 Pt 2):R1118-25
pubmed: 1951759
Am J Physiol Renal Physiol. 2017 Feb 1;312(2):F245-F253
pubmed: 27122543
Hypertension. 2011 Mar;57(3):355-62
pubmed: 21282552
Hypertension. 2013 Oct;62(4):731-7
pubmed: 23959560
Am J Physiol. 1979 Sep;237(3):F232-40
pubmed: 474764
Clin J Am Soc Nephrol. 2007 Mar;2(2):196-7
pubmed: 17699405
Hypertension. 2003 May;41(5):1143-50
pubmed: 12682079
Science. 2010 Jan 22;327(5964):459-63
pubmed: 20093472
J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1149-58
pubmed: 25757657
Am J Physiol Renal Physiol. 2007 Aug;293(2):F526-32
pubmed: 17507604
Circ Res. 2010 Oct 1;107(7):934-8
pubmed: 20689062
J Hypertens. 2007 Dec;25(12):2441-53
pubmed: 17984666
Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R943-9
pubmed: 15191907
Am J Physiol Renal Physiol. 2010 Nov;299(5):F917-28
pubmed: 20826569
Nat Med. 2013 May;19(5):557-66
pubmed: 23652116
Obesity (Silver Spring). 2014 Oct;22(10):2201-9
pubmed: 25044950
Am J Physiol Renal Physiol. 2008 Sep;295(3):F772-9
pubmed: 18579707
Curr Opin Pharmacol. 2011 Apr;11(2):180-6
pubmed: 21339086
Mol Metab. 2016 Aug 23;5(10):959-969
pubmed: 27689008
Am J Hypertens. 2015 Dec;28(12):1418-26
pubmed: 25968123
Hypertension. 2007 Feb;49(2):365-72
pubmed: 17200435
J Am Soc Nephrol. 2010 Jan;21(1):18-23
pubmed: 19917780
Cell Metab. 2011 Apr 6;13(4):469-475
pubmed: 21459331